{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:02:16Z","timestamp":1787983336983,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["11\/100\/50"],"award-info":[{"award-number":["11\/100\/50"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A13363"],"award-info":[{"award-number":["A13363"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["162082"],"award-info":[{"award-number":["162082"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["171339"],"award-info":[{"award-number":["171339"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","award":["158519"],"award-info":[{"award-number":["158519"]}],"id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["163301"],"award-info":[{"award-number":["163301"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","award":["163026"],"award-info":[{"award-number":["163026"]}],"id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"publisher","award":["158046"],"award-info":[{"award-number":["158046"]}],"id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3322-7","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T23:04:10Z","timestamp":1559084650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons"],"prefix":"10.1186","volume":"20","author":[{"name":"for the STAMPEDE and FOCUS4 investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-7799","authenticated-orcid":false,"given":"Dominic","family":"Hague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-6999","authenticated-orcid":false,"given":"Stephen","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-8065","authenticated-orcid":false,"given":"Lindsey","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-8270","authenticated-orcid":false,"given":"Mary","family":"Rauchenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Van Looy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9082-4596","authenticated-orcid":false,"given":"Carlos","family":"Diaz-Montana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-0571","authenticated-orcid":false,"given":"Melissa","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-8204","authenticated-orcid":false,"given":"Nicholas","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1700","authenticated-orcid":false,"given":"Mahesh K. B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-6634","authenticated-orcid":false,"given":"Louise","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"3322_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13063-016-1273-9","volume":"17","author":"I Hatfield","year":"2016","unstructured":"Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials. 2016;17:150.","journal-title":"Trials"},{"key":"3322_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62\u201370.","journal-title":"N Engl J Med"},{"key":"3322_CR3","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/sim.1430","volume":"22","author":"P Royston","year":"2003","unstructured":"Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med. 2003;22:2239\u201356.","journal-title":"Stat Med"},{"key":"3322_CR4","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2013.50.7905","volume":"31","author":"R Kaplan","year":"2013","unstructured":"Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol. 2013;31:4562\u20138.","journal-title":"J Clin Oncol"},{"key":"3322_CR5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdw413","volume":"28","author":"LA Renfro","year":"2017","unstructured":"Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2017;28:34\u201343.","journal-title":"Ann Oncol"},{"key":"3322_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1740774517725697","volume":"14","author":"MK Parmar","year":"2017","unstructured":"Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, et al. Testing many treatments within a single protocol over 10 years at MRC CTU at UCL: multi-arm, multi stage platform, umbrella and basket protocols. Clin Trials. 2017;14:451\u201361.","journal-title":"Clin Trials"},{"key":"3322_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1745-6215-13-168","volume":"13","author":"MR Sydes","year":"2012","unstructured":"Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.","journal-title":"Trials"},{"key":"3322_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1740774515626362","volume":"13","author":"BR Saville","year":"2016","unstructured":"Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13:358\u201366.","journal-title":"Clin Trials"},{"key":"3322_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(14)61122-3","volume":"384","author":"MKB Parmar","year":"2014","unstructured":"Parmar MKB, Carpenter J, Sydes MR. More multi arm randomised trials of superiority are needed. Lancet. 2014;384:283\u20134.","journal-title":"Lancet"},{"key":"3322_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/0962280212465498","volume":"25","author":"J Wason","year":"2016","unstructured":"Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res. 2016;25:716\u201327.","journal-title":"Stat Methods Med Res"},{"key":"3322_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1745-6215-10-39","volume":"10","author":"MR Sydes","year":"2009","unstructured":"Sydes MR, Parmar MKB, James ND, Clarke NW, Dearnaley DP, Mason MD, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials. 2009;10:39.","journal-title":"Trials"},{"key":"3322_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","volume":"20","author":"ND James","year":"2008","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer\u2014a multi-arm multi-stage randomised controlled trial. Clin Oncol (R Coll Radiol). 2008;20:577\u201381.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3322_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"3322_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"3322_CR15","first-page":"35","volume":"4","author":"R Kaplan","year":"2015","unstructured":"Kaplan R. The FOCUS4 design for biomarker stratified trials. Chin Clin Oncol. 2015;4:35.","journal-title":"Chin Clin Oncol"},{"key":"3322_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2468-1253(17)30394-1","volume":"3","author":"R Adams","year":"2018","unstructured":"Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, et al. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. Lancet Gastroenterol Hepatol. 2018;3:162\u201371.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3322_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/0253-7613.93842","volume":"44","author":"B Krishnankutty","year":"2012","unstructured":"Krishnankutty B, Bellary S, Kumar NBR, Moodahadu LS. Data management in clinical research: an overview. Indian J Pharmacol. 2012;44:168\u201372.","journal-title":"Indian J Pharmacol"},{"key":"3322_CR18","first-page":"350","volume":"8","author":"N Bajpai","year":"2015","unstructured":"Bajpai N. Metrics for leveraging more in clinical data management: proof of concept in the context of vaccine trials in an Indian pharmaceutical company. Asian J Pharm Clin Res. 2015;8:350\u20137.","journal-title":"Asian J Pharm Clin Res"},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1740774510361542","volume":"7","author":"J Quinlan","year":"2010","unstructured":"Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials. 2010;7:167\u201373.","journal-title":"Clin Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3322-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T23:16:31Z","timestamp":1590621391000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3322-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DH, ST, LM, MR, NVL, CDM, MP, LB and MRS are all employed by the Medical Research Council, a publicly funded body in the United Kingdom that is sponsoring both trials. The other author(s) declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"294"}}